Everhart Financial Group Inc. Buys 632 Shares of Danaher Co. (NYSE:DHR)

Everhart Financial Group Inc. increased its stake in Danaher Co. (NYSE:DHR) by 25.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,084 shares of the conglomerate’s stock after buying an additional 632 shares during the quarter. Everhart Financial Group Inc.’s holdings in Danaher were worth $771,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Cary Street Partners Investment Advisory LLC increased its stake in Danaher by 20.2% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock worth $2,112,000 after purchasing an additional 1,533 shares during the period. Cercano Management LLC increased its stake in Danaher by 11.4% in the fourth quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock worth $46,862,000 after purchasing an additional 20,715 shares during the period. Donaldson Capital Management LLC increased its stake in Danaher by 5.8% in the first quarter. Donaldson Capital Management LLC now owns 1,469 shares of the conglomerate’s stock worth $367,000 after purchasing an additional 80 shares during the period. Caden Capital Partners LP increased its stake in Danaher by 12.4% in the fourth quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock worth $32,172,000 after purchasing an additional 15,313 shares during the period. Finally, Legacy Financial Advisors Inc. increased its stake in Danaher by 2.4% in the fourth quarter. Legacy Financial Advisors Inc. now owns 2,377 shares of the conglomerate’s stock worth $550,000 after purchasing an additional 55 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Up 0.6 %

Shares of DHR stock traded up $1.65 during trading hours on Friday, reaching $269.48. 1,365,228 shares of the company’s stock were exchanged, compared to its average volume of 2,820,898. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70. The stock has a market cap of $199.60 billion, a PE ratio of 45.67, a PEG ratio of 4.62 and a beta of 0.83. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The stock’s fifty day moving average price is $258.72 and its two-hundred day moving average price is $254.34.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company’s revenue was down 2.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.05 earnings per share. Research analysts predict that Danaher Co. will post 7.59 EPS for the current year.

Insider Activity at Danaher

In related news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. The disclosure for this sale can be found here. Insiders have sold a total of 38,707 shares of company stock worth $10,786,944 over the last quarter. Insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on DHR. Evercore ISI decreased their price objective on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Barclays lifted their price objective on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, July 24th. The Goldman Sachs Group lifted their price objective on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Stifel Nicolaus lifted their price objective on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Finally, TD Cowen lifted their price objective on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Six equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $276.88.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.